RSS feed

Publications (original articles or review articles) published in 2022 from OUS - Department of Gynaecological Oncology

16 publications found

Baranovicova E, Racay P, Zubor P, Smolar M, Kudelova E, Halasova E, Dvorska D, Dankova Z (2022)
Circulating metabolites in the early stage of breast cancer were not related to cancer stage or subtypes but associated with ki67 level. Promising statistical discrimination from controls
Mol Cell Probes, 66, 101862
DOI 10.1016/j.mcp.2022.101862, PubMed 36162596

Brunetti M, Panagopoulos I, Vitelli V, Andersen K, Hveem TS, Davidson B, Eriksson AGZ, Trent PKB, Heim S, Micci F (2022)
Endometrial Carcinoma: Molecular Cytogenetics and Transcriptomic Profile
Cancers (Basel), 14 (14)
DOI 10.3390/cancers14143536, PubMed 35884597

Davidson B, Elstrand MB (2022)
Clinicopathological prognostic parameters in patients with tubo-ovarian carcinoma effusions
Cytopathology, 33 (4), 479-492
DOI 10.1111/cyt.13126, PubMed 35398934

Daviu C, Blaakaer J, Eriksson AGZ, Herrstedt J, Vandborg MP, Rasmussen AMO, Fuglsang K (2022)
Nonepithelial ovarian cancer - the current clinical practice in the Nordic countries. Survey from the surgical subcommittee of the Nordic society of gynecological oncology (NSGO)
Acta Oncol, 61 (8), 939-945
DOI 10.1080/0284186X.2022.2088249, PubMed 35762031

Gatius S, Velasco A, Varela M, Cuatrecasas M, Jares P, Setaffy L, Bonhomme B, Santon A, Lindemann K, Croce S, Davidson B, Lax S, Palacios J, Matias-Guiu X (2022)
Comparison of the Idylla™ MSI assay with the Promega™ MSI Analysis System and immunohistochemistry on formalin-fixed paraffin-embedded tissue of endometrial carcinoma: results from an international, multicenter study
Virchows Arch, 480 (5), 1031-1039
DOI 10.1007/s00428-022-03291-x, PubMed 35124717

Kurnit KC, Nobre SP, Fellman BM, Iglesias DA, Lindemann K, Jhingran A, Eriksson AGZ, Ataseven B, Glaser GE, Mueller JJ, Westin SN, Soliman PT (2022)
Adjuvant therapy in women with early stage uterine serous carcinoma: A multi-institutional study
Gynecol Oncol, 167 (3), 452-457
DOI 10.1016/j.ygyno.2022.09.025, PubMed 36243601

Madland K, Bjorge L, Småstuen MC, Dørum A, Vistad I (2022)
Symptomatic or asymptomatic recurrence of ovarian cancer: does it influence survival?
Int J Gynecol Cancer (in press)
DOI 10.1136/ijgc-2022-003361, PubMed 35680138

Marth C, Abreu MH, Andersen KK, Aro KM, de Lurdes Batarda M, Boll D, Ekmann-Gade AW, Haltia UM, Hansen J, Haug AJ, Høgdall C, Korach J, Lassus H, Lindemann K, Van Nieuwenhuysen E, Ottevanger PB, Polterauer S, Schnack TH (2022)
Real-life data on treatment and outcomes in advanced ovarian cancer: An observational, multinational cohort study (RESPONSE trial)
Cancer, 128 (16), 3080-3089
DOI 10.1002/cncr.34350, PubMed 35714310

Nilsen A, Hillestad T, Skingen VE, Aarnes EK, Fjeldbo CS, Hompland T, Evensen TS, Stokke T, Kristensen GB, Grallert B, Lyng H (2022)
miR-200a/b/-429 downregulation is a candidate biomarker of tumor radioresistance and independent of hypoxia in locally advanced cervical cancer
Mol Oncol, 16 (6), 1402-1419
DOI 10.1002/1878-0261.13184, PubMed 35064630

O'Cearbhaill RE, Pérez-Fidalgo JA, Monk BJ, Tusquets I, McCormick C, Fuentes J, Moore RG, Vulsteke C, Shahin MS, Forget F, Bradley WH, Hietanen S, O'Malley DM, Dørum A, Slomovitz BM, Baumann K, Selle F, Calvert PM, Artioli G, Levy T, Kumar A, Malinowska IA, Li Y, Gupta D, González-Martín A (2022)
Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study
Gynecol Oncol, 166 (1), 36-43
DOI 10.1016/j.ygyno.2022.04.012, PubMed 35550709

Paulsen T, Liland H, Myklebust TÅ, Lindemann K (2022)
Early referral to a palliative team improves end-of-life care among gynecological cancer patients: a retrospective, population-based study
Int J Gynecol Cancer, 32 (2), 181-188
DOI 10.1136/ijgc-2021-002898, PubMed 34987096

Pfisterer J, Joly F, Kristensen G, Rau J, Mahner S, Pautier P, El-Balat A, Kurtz JE, Canzler U, Sehouli J, Heubner ML, Hartkopf AD, Baumann K, Hasenburg A, Hanker LC, Belau A, Schmalfeldt B, Denschlag D, Park-Simon TW, Selle F, Jackisch C, Burges A, Lück HJ, Emons G, Meier W et al. (2022)
Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial
J Clin Oncol, 41 (4), 893-902
DOI 10.1200/JCO.22.01010, PubMed 36332161

Poveda A, Lheureux S, Colombo N, Cibula D, Lindemann K, Weberpals J, Bjurberg M, Oaknin A, Sikorska M, González-Martín A, Madry R, Pérez MJR, Ledermann J, Davidson R, Blakeley C, Bennett J, Barnicle A, Škof E (2022)
Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis
Gynecol Oncol, 164 (3), 498-504
DOI 10.1016/j.ygyno.2021.12.025, PubMed 35063276

Siegenthaler F, Lindemann K, Epstein E, Rau TT, Nastic D, Ghaderi M, Rydberg F, Mueller MD, Carlson J, Imboden S (2022)
Time to first recurrence, pattern of recurrence, and survival after recurrence in endometrial cancer according to the molecular classification
Gynecol Oncol, 165 (2), 230-238
DOI 10.1016/j.ygyno.2022.02.024, PubMed 35277281

Skipar K, Hompland T, Lund KV, Løndalen A, Malinen E, Kristensen GB, Lindemann K, Nakken ES, Bruheim K, Lyng H (2022)
Risk of recurrence after chemoradiotherapy identified by multimodal MRI and 18F-FDG-PET/CT in locally advanced cervical cancer
Radiother Oncol, 176, 17-24
DOI 10.1016/j.radonc.2022.09.002, PubMed 36113778

Utne I, Stokke K, Ritchie C, Løyland B, Grov EK, Rasmussen HL, Lindemann K, Paul SM, Torstveit AH, Miaskowski C (2022)
Changes in Subjective Measures of Cognitive Function in Older Adults From the Initiation Through 12 Months After the Receipt of Chemotherapy
Cancer Nurs (in press)
DOI 10.1097/NCC.0000000000001140, PubMed 35781267